Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-195,800
Closed -$13.1M 2049
2024
Q3
$13.1M Buy
195,800
+137,500
+236% +$11.3M 0.03% 397
2024
Q2
$6.61M Sell
58,300
-26,300
-31% -$3.33M 0.01% 701
2024
Q1
$11.7M Sell
84,600
-137,000
-62% -$17.2M 0.02% 440
2023
Q4
$27.5M Buy
221,600
+101,300
+84% +$10.3M 0.05% 245
2023
Q3
$11.2M Buy
+120,300
New +$13.6M 0.02% 554

Other funds holding DXCM

GTS Securities's DXCM Position: Q2 2026 in Review

GTS Securities sold out of DexCom (DXCM) in Q2 2026, closing a stake of 4,362 shares — an estimated $274K sold.

GTS Securities first reported a position in DXCM in Q2 2023 and held it in 10 quarters. The position peaked at $2.63M in Q3 2024. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • GTS Securities reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 4,362 DexCom shares in Q2 2026, an estimated $274K.
  • GTS Securities first reported a position in DexCom in Q2 2023 and held it in 10 quarters.
  • GTS Securities's DexCom position peaked at $2.63M in Q3 2024.
  • 974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.